Losartan and Prednisone Interaction: Risks, Monitoring, and Clinical Guidance

Is there a direct interaction between losartan and prednisone?

The losartan label's drug-interactions section covers four categories: other drugs that raise serum potassium, lithium, NSAIDs including COX-2 inhibitors, and dual blockade of the renin-angiotensin system with an ACE inhibitor, another ARB or aliskiren [1]. Prednisone is not listed [1].

Losartan itself is an active angiotensin receptor blocker, and about 14% of an oral dose is converted to a more potent active carboxylic acid metabolite. The label concludes this conversion is mediated primarily by CYP2C9 rather than CYP3A4 [1]. In a crossover study of 11 healthy volunteers, fluconazole cut that metabolite's AUC to 47% of control and its peak concentration to 30%, while itraconazole had no significant effect on losartan or the metabolite [6]. These results describe losartan with two antifungals, not with prednisone.

Potassium

The losartan label carries a hyperkalemia warning. It says to monitor serum potassium periodically, that dose reduction or discontinuation may be required, and that other drugs which raise serum potassium can add to the risk [1]. In the RENAAL nephropathy trial of 1,513 patients, hyperkalemia was among the adverse events reported in 4% or more of losartan patients and at least 2 percentage points more often than with placebo [1]. The prednisone label lists potassium loss, salt and water retention and high blood pressure among corticosteroid effects.

Kidney function

Losartan's label warns that drugs blocking the renin-angiotensin system can change renal function, including acute renal failure. It names renal artery stenosis, chronic kidney disease, severe congestive heart failure and volume depletion as particular risks. The label says to monitor renal function periodically in those patients and to consider withholding or discontinuing losartan if renal function falls significantly [1].

The label also calls out NSAIDs: in older, volume-depleted or renally impaired patients they can worsen renal function, and they can blunt losartan's blood-pressure effect [1].

Separately, steroid plus NSAID is a recognized ulcer combination. In a Tennessee Medicaid case-control study of 1,415 ulcer cases and 7,063 controls, the relative risk associated with current oral corticosteroid use was 4.4 (2.0 to 9.7) in people also taking an NSAID and 1.1 (0.5 to 2.1) in those not taking one. People taking both drugs had about 15 times the risk of people taking neither [4]. A meta-analysis of 159 randomized trials (33,253 patients) put the odds of gastrointestinal bleeding or perforation with corticosteroids at 1.43 (1.22 to 1.66). The increase was significant in hospitalized patients but not in ambulatory patients, among whom 0.13% had an event [7].

What about blood sugar?

Corticosteroids raise blood glucose, and not only in people who already have diabetes. A single-center review of 50 hospitalized patients who received at least 40 mg/day of prednisone equivalent for at least two days found 32 (64%) had a glucose of 200 mg/dL or higher. Among the 34 with no diabetes history, 19 (56%) had at least one reading that high [2]. It is a small hospital series, but it shows that steroid hyperglycemia reaches people without a diabetes diagnosis.

Short steroid courses carry risks

In a study of 1,548,945 US adults with commercial insurance, 21.1% received at least one short course of oral corticosteroid (under 30 days) over three years. Within 30 days of starting, the study found higher rates of sepsis (incidence rate ratio 5.30, 95% CI 3.80 to 7.41), venous thromboembolism (3.33, 2.78 to 3.99) and fracture (1.87, 1.69 to 2.07). The excess persisted at prednisone-equivalent doses under 20 mg/day [3]. The design was observational.

Steroid risks that arrive regardless of losartan

Bone: the 2022 American College of Rheumatology guideline strongly recommends early fracture-risk assessment for adults on at least 2.5 mg/day of glucocorticoids for more than 3 months. It uses clinical fracture assessment, bone mineral density with vertebral fracture assessment, and FRAX in those 40 or older, with drug treatment for people at medium, high or very high risk [5]. Risk is dose dependent. In a UK cohort of 244,235 oral corticosteroid users and matched controls, relative rates were 1.61 for hip fracture and 2.60 for vertebral fracture. The vertebral fracture rate rose from 1.55 below 2.5 mg/day to 5.18 at 7.5 mg/day or more [8].

Infection: pooled data from 71 controlled trials found infectious complications in 12.7% of 2,111 patients on systemic corticosteroids versus 8.0% of 2,087 controls (relative risk 1.6, 1.3 to 1.9). The rate was not increased below 10 mg/day or below a 700 mg cumulative dose of prednisone [9].